A discussion between Dr. Daniel A. Pollyea and Dr. Florian Kuchenbauer (September 2022) In the second episode of the 2022 AML series, Dr. Pollyea and Dr. Kuchenbauer review data presented at the EHA 2022 annual meeting. After zooming in on the QuANTUM-First trial with quizartinib and further discussing treatment strategies and opportunities for FLT3 positive AML, such as the triplet combination of quirzatinib, decitabine and venetoclax, they touch upon promising data with magrolimab, a first-in-class anti-CD47 antibody, in combination with azacitidine in AML patients with the TP53 mutation. Daniel A. Pollyea, MD, MS, Associate Professor of Medicine, Clinical Director of Leukemia Services, Robert H. Allen MD Chair in Hematology Research, Division of Hematology, University of Colorado, School of Medicine Florian Kuchenbauer, MD, PhD, FRCPC, Member, Leukemia/Bone Marrow Transplant Program of BC, Associate Director, Hematology Research Program, Michael Smith Health Research BC Scholar, Associate Professor, Department of Medicine, University of British of Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
